OBJECTIVE: The aim of this study was to evaluate the effects of different types of hormone replacement therapy (HRT) on mammographic density. MATERIALS AND METHODS: In a prospective 1-year study, 103 postmenopausal women were randomized to receive tibolone 2.5 mg/die, continuous conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate (MPA) 5mg/die or placebo. Mammograms were performed at baseline and after 12 months of treatment. Mammographic density was quantified according to the Wolfe classification. RESULTS: After 12 months of HRT 16 of the 35 patients (45.1%) receiving continuous combined hormonal therapy showed an increase of breast density change in the Wolfe classification. After treatment with tibolone, an up grading in breast density, according to Wolfe's classification, was found in 2 of the 43 patients (2.3%). No changes were recorded in the 25 patients of the control group. The difference between the group treated with continuous combined hormonal therapy and the control group was highly significant (p<0.001). The difference in breast density between patients in treatment with tibolone and the control group was not statistically significant (p=0.34). DISCUSSION: Continuous combination HRT may be more commonly associated with an increase of mammography density than tibolone treatment.
RCT Entities:
OBJECTIVE: The aim of this study was to evaluate the effects of different types of hormone replacement therapy (HRT) on mammographic density. MATERIALS AND METHODS: In a prospective 1-year study, 103 postmenopausal women were randomized to receive tibolone 2.5 mg/die, continuous conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate (MPA) 5mg/die or placebo. Mammograms were performed at baseline and after 12 months of treatment. Mammographic density was quantified according to the Wolfe classification. RESULTS: After 12 months of HRT 16 of the 35 patients (45.1%) receiving continuous combined hormonal therapy showed an increase of breast density change in the Wolfe classification. After treatment with tibolone, an up grading in breast density, according to Wolfe's classification, was found in 2 of the 43 patients (2.3%). No changes were recorded in the 25 patients of the control group. The difference between the group treated with continuous combined hormonal therapy and the control group was highly significant (p<0.001). The difference in breast density between patients in treatment with tibolone and the control group was not statistically significant (p=0.34). DISCUSSION: Continuous combination HRT may be more commonly associated with an increase of mammography density than tibolone treatment.
Authors: Diana S M Buist; Melissa L Anderson; Susan D Reed; Erin J Aiello Bowles; E Dawn Fitzgibbons; Juleann C Gandara; Deborah Seger; Katherine M Newton Journal: Ann Intern Med Date: 2009-06-02 Impact factor: 25.391
Authors: Rachel Mintz; Mei Wang; Shuai Xu; Graham A Colditz; Chris Markovic; Adetunji T Toriola Journal: Breast Cancer Res Date: 2022-04-14 Impact factor: 6.466
Authors: Emily Banks; Gillian Reeves; Valerie Beral; Diana Bull; Barbara Crossley; Moya Simmonds; Elizabeth Hilton; Stephen Bailey; Nigel Barrett; Peter Briers; Ruth English; Alan Jackson; Elizabeth Kutt; Janet Lavelle; Linda Rockall; Matthew G Wallis; Mary Wilson; Julietta Patnick Journal: Breast Cancer Res Date: 2005-12-23 Impact factor: 6.466